HER2This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. Subscribe to this data using MyMedWorm.Subscribe to this data using GoogleReader.Subscribe to this data using Bloglines.Subscribe to this data using MyYahoo.

This page shows you your search results in order of date.

Pages: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30

2476 records returned

Lapatinib monotherapy feasible for HER2-positive metastatic breast cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Lapatinib monotherapy is an effective treatment for patients with human epidermal growth factor receptor 2-positive advanced or metastatic breast cancer that has relapsed after trastuzumab treatment, Japanese research suggests. (Source: MedWire News - Breast Cancer)
Source: MedWire News - Breast Cancer - November 20, 2009 Category: Cancer & Oncology Source Type: news

Lapatinib monotherapy feasible for HER2-positive metastatic breast cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Lapatinib monotherapy is an effective treatment for patients with human epidermal growth factor receptor 2-positive advanced or metastatic breast cancer that has relapsed after trastuzumab treatment, Japanese research suggests. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - November 20, 2009 Category: Cancer & Oncology Source Type: news

In vitro and in vivo evidence that a combination of lapatinib plus S-1 is a promising treatment for pancreatic cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Lapatinib is a small molecule inhibitor of both HER2 and the epidermal growth factor receptor (EGFR). We investigated the effect of treatment with lapatinib alone or in combination with a fluoropyrimidine derivative S-1 against pancreatic cancer. The HER2/EGFR expression in each of the four pancreatic cancer cell lines MiaPaca-2, PANC-1, Capan-1 and Capan-2 was measured by flow cytometry. The anti-tumor effects of lapatinib (30 mg/kg) and/or S-1 (10 mg/kg) were evaluated using female BALB/c nude mice xenografts generated using these four cell lines. Synergy between lapatinib and S-1 was examined by median effect analysis i...
Source: Cancer Science - November 20, 2009 Category: Cancer & Oncology Authors: Masahiro Komoto, Bunzo Nakata, Takafumi Nishii, Hidemi Kawajiri, Osamu Shinto, Ryosuke Amano, Nobuya Yamada, Masakazu Yashiro, Kosei Hirakawa Source Type: journals

Disruption of the blood brain barrier by brain metastases of triple-negative and basal-type breast cancer but not HER2/neu-positive breast cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Generally, the blood-brain barrier (BBB) of brain metastasis was thought to be disrupted.We retrospectively performed immunohistochemical staining for glucose transporter 1 (GLUT1) and breast cancer resistance protein (BCRP) to evaluate the status of the BBB in resected brain metastases. Associations between expression of GLUT1 and/or BCRP and the immunohistochemical profiles of breast cancers, such as the statuses of hormone receptors, human epidermal growth factor receptor 2 (HER2/neu), and a basal-type marker (cytokeratin 5/6, HER1), were also analyzed.The study included 29 breast cancer patients with brain metastasis w...
Source: Cancer - November 20, 2009 Category: Cancer & Oncology Authors: Kan Yonemori, Koji Tsuta, Makiko Ono, Chikako Shimizu, Akihiro Hirakawa, Tadashi Hasegawa, Yutaka Hatanaka, Yoshitaka Narita, Soichiro Shibui, Yasuhiro Fujiwara Source Type: journals

[Abnormal expression of beta-catenin and E-cadherin in Her2-positive breast cancer and its implications.]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CONCLUSION: A direct correlation between positive Her2 expression and abnormal beta-catenin expression exists in human breast carcinoma, and positive Her2 expression may have functional interactions with abnormal activation of Wnt/beta-catenin signaling pathway. PMID: 19923077 [PubMed - as supplied by publisher] (Source: Journal of Southern Medical University)
Source: Journal of Southern Medical University - November 20, 2009 Category: Universities & Medical Training Authors: Niu LG, He JJ, Wang K, Zhang W, Zhou C Tags: Nan Fang Yi Ke Da Xue Xue Bao Source Type: journals

FNCLCC-PACS 04 trial of trastuzumab for patients with axillary-node-positive breast cancer finds no benefit in adjuvant settingEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Source: J Clin Oncol Area: News The PACS04 trial initiated in 2001 aimed to evaluate the efficacy of concomitant use of docetaxel with anthracyclines, and the efficacy of trastuzumab given for 1 year after the end of adjuvant chemotherapy in patients with axillary node-positive breast cancer. In this paper, results of the second randomisation (i.e. evaluation of trastuzumab efficacy in the adjuvant setting in human epidermal growth factor receptor 2 (HER2)-positive patients -FNCLCC-PACS 04 trial) are reported. The initial study involved 3010 patients with operable node-positive breast cancer who were randomised...
Source: NeLM - Oncology - November 19, 2009 Category: Cancer & Oncology Source Type: organizations

Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study [Breast Cancer]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion Trastuzumab plus anastrozole improves outcomes for patients with HER2/hormone receptor–copositive MBC compared with anastrozole alone, although adverse events and serious adverse events were more frequent with the combination. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 18, 2009 Category: Cancer & Oncology Authors: Kaufman, Mackey, Clemens, Bapsy, Vaid, Wardley, Tjulandin, Jahn, Lehle, Feyereislova, Revil, Jones Tags: Chemotherapy, Breast Cancer Source Type: journals

Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor-Positive Metastatic Breast Cancer [Breast Cancer]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion This trial demonstrated that a combined targeted strategy with letrozole and lapatinib significantly enhances PFS and clinical benefit rates in patients with MBC that coexpresses HR and HER2. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 18, 2009 Category: Cancer & Oncology Authors: Johnston, Pippen, Pivot, Lichinitser, Sadeghi, Dieras, Gomez, Romieu, Manikhas, Kennedy, Press, Maltzman, Florance, O'Rourke, Oliva, Stein, Pegram Tags: Combined Modality Breast Cancer Source Type: journals

Prognostic and Predictive Value of HER2 Extracellular Domain in Metastatic Breast Cancer Treated With Lapatinib and Paclitaxel in a Randomized Phase III Study [Breast Cancer]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion HER2 bECD does not predict lapatinib benefit in patients with HER2-negative MBC. Changes in ECD status correlates with patient outcome regardless of treatment given. Measuring HER2 ECD is not currently recommended for predicting benefit to lapatinib. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 18, 2009 Category: Cancer & Oncology Authors: Finn, Gagnon, Di Leo, Press, Arbushites, Koehler Tags: Chemotherapy, Combined Modality, Clinical Trials, Breast Cancer Source Type: journals

Targeted therapy of metastatic breast cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract Breast cancer is a heterogeneous disease characterised by a dysregulation of multiple pathways related to cell differentiation, cell cycle control, apoptosis, angiogenesis and development of metastasis. Acting against these pathways provides therapeutic targets for new targeted biologic therapies, which, in the future, might constitute a key for fighting cancer. The development of molecular technology in recent years has allowed a further comprehension of these mutations and dysregulated pathways leading to oncogenesis. New targeted biologic therapies will block essential functions of cancer cells a...
Source: Clinical and Translational Oncology - November 18, 2009 Category: Cancer & Oncology Tags: Clinical and Translational Oncology Source Type: journals

Applications submitted to FDA for bevacizumab (Avastin®) in first-line treatment of metastatic breast cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Source: BioSpace Area: News According to BioSpace, Genentech has submitted two supplemental Biologics License Applications (sBLAs) to the U.S. FDA for bevacizumab (Avastin®) for the first-line treatment of women with advanced (metastatic) HER2-negative breast cancer. One sBLA is based on the Phase III AVADO study that compared bevacizumab in combination with docetaxel chemotherapy, to docetaxel alone in this setting. The other is based on the Phase III RIBBON 1 study that investigated bevacizumab in combination with a taxane, anthracycline-based or capecitabine chemotherapy (compared with the chemotherapies al...
Source: NeLM - Oncology - November 18, 2009 Category: Cancer & Oncology Source Type: organizations

Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition [Medical_Sciences]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Non-small cell lung cancers with activating mutations in the epidermal growth factor receptor (EGFR) are highly responsive to EGFR tyrosine... (Source: Proceedings of the National Academy of Sciences)
Source: Proceedings of the National Academy of Sciences - November 17, 2009 Category: Science Authors: Faber, A. C., Li, D., Song, Y., Liang, M.-C., Yeap, B. Y., Bronson, R. T., Lifshits, E., Chen, Z., Maira, S.-M., Garcia-Echeverria, C., Wong, K.-K., Engelman, J. A. Tags: Medical_Sciences Source Type: journals

Genentech Submits Supplemental Applications To FDA For Avastin Combined With Commonly Used Chemotherapies For Women With Advanced Breast CancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Genentech, Inc., a wholly-owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the company submitted two supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration (FDA) for Avastin® (bevacizumab) for the treatment of women who have not received chemotherapy for advanced (metastatic) HER2-negative breast cancer (first-line treatment). (Source: Breast Cancer News From Medical News Today)
Source: Breast Cancer News From Medical News Today - November 17, 2009 Category: Cancer & Oncology Tags: Breast Cancer Source Type: news

Women with small HER2+ breast ca face recurrence riskEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Researchers in the U.S. and Italy report that women with HER2-positive breast cancers that are 1 cm or less in diameter and are node-negative have a risk of recurrence that is two to five times greater than that of women with HER2-negative breast cancers (J Clin Oncol online, November 2, 2009). (Source: Cancer Network)
Source: Cancer Network - November 17, 2009 Category: Cancer & Oncology Source Type: info

Applications to allow Avastin to be combined with commonly used chemotherapies in advanced breast cancer submitted to FDAEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Roche announced today that Genentech, a wholly-owned member of the Roche Group, has submitted two supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration (FDA) for Avastin® (bevacizumab) for the treatment of women who have not received chemotherapy for advanced (metastatic) HER2-negative breast cancer (first-line treatment). One sBLA is based on the phase III AVADO study that investigated Avastin in combination with docetaxel chemotherapy. The other is based on the phase III RIBBON-1 study that investigated Avastin in combination with a taxane or anthracycline-based chemotherapy or...
Source: Roche Investor Update - November 17, 2009 Category: Pharmaceuticals Source Type: organizations

Protein Kinase A Activation Confers Resistance to Trastuzumab in Human Breast Cancer Cell Lines.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CONCLUSIONS: Activation of PKA signaling may be one mechanism contributing to trastuzumab resistance in Her2-positive breast cancer. We propose a molecular model by which PKA confers its effects. (Clin Cancer Res 2009;15(23):OF1-11). PMID: 19920112 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - November 17, 2009 Category: Cancer & Oncology Authors: Gu L, Lau SK, Loera S, Somlo G, Kane SE Tags: Clin Cancer Res Source Type: journals

Loss of HER2 Amplification Following Trastuzumab-Based Neoadjuvant Systemic Therapy and Survival Outcomes.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CONCLUSION: High pCR rates are achieved in patients with HER2-positive breast cancer treated with neoadjuvant trastuzumab in combination with anthracyclines and taxanes. One third of patients with significant residual disease loses HER2 amplification, and this change is associated with poor RFS. Residual tumor identified at the time of surgery should be reassessed for HER2 status, and novel adjuvant therapy strategies need to be studied in this population. (Clin Cancer Res 2009;15(23):OF1-8). PMID: 19920100 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - November 17, 2009 Category: Cancer & Oncology Authors: Mittendorf EA, Wu Y, Scaltriti M, Meric-Bernstam F, Hunt KK, Dawood S, Esteva FJ, Buzdar AU, Chen H, Eksambi S, Hortobagyi GN, Baselga J, Gonzalez-Angulo AM Tags: Clin Cancer Res Source Type: journals

Concordant HER2 status between metastatic breast cancer cells in CSF and primary breast cancer tissueEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract It is not known whether the HER2 status of malignant CSF cells coincides with that of the original breast carcinoma cells. We investigated whether CSF cytology specimens were suitable to evaluate HER2 status by fluorescence in situ hybridization (FISH) in patient with leptomeningeal metastasis (LM). Both formalin-fixed paraffin-embedded (FFPE) breast cancer tissue and liquid based CSF cytology specimens were evaluated for HER2 status in 16 patients with LM. We evaluated HER2 gene amplification using FISH on destained CSF cytology slides containing a minimum of 20 malignant cells per slide, and compa...
Source: Breast Cancer Research and Treatment - November 14, 2009 Category: Cancer & Oncology Tags: Breast Cancer Research and Treatment Source Type: journals

High Risk of Recurrence for Patients With Breast Cancer Who Have Human Epidermal Growth Factor Receptor 2–Positive, Node-Negative Tumors 1 cm or SmallerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In this retrospective study of 935 patients, T1a/T1b HER2-positive breast cancer was associated with more aggressive biology and higher risk of recurrence. The results were validated in a separate cohort... Related... (Source: OncologySTAT Journal Scans)
Source: OncologySTAT Journal Scans - November 14, 2009 Category: Cancer & Oncology Source Type: journals

Clinical Relevance of HER2 Overexpression/Amplification in Patients With Small Tumor Size and Node-Negative Breast CancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In this retrospective analysis of 150 patients with HER2-positive pT1a/bN0M0 breast cancer and 229 matched controls, HER2-positive status was associated with a significantly higher risk of recurrence than... Related... (Source: OncologySTAT Journal Scans)
Source: OncologySTAT Journal Scans - November 14, 2009 Category: Cancer & Oncology Source Type: journals

Study Finds It's Safe To Treat HER2-Positive Breast Cancer With Trastuzumab And Adjuvant RadiationEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Standard adjuvant treatment for HER2-positive breast cancer patients, following primary surgery for their cancer, is Trastuzumab (Herceptin)--typically used in combination with chemotherapy. (Source: Cancercompass News: Breast Cancer)
Source: Cancercompass News: Breast Cancer - November 14, 2009 Category: Cancer & Oncology Source Type: news

Fifteen-year trends in metastatic breast cancer survival in GreeceEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In this study, information is based on a total of 1361 patients with a median follow up of 3.7 years and median survival of 1.9 years (median survival 1.28, 1.68, 2.20, and 2.57 years for 1991–1994, 1995–1998, 1999–2002, and 2003–2006, respectively). Survival improved significantly across diagnosis time periods, by 25, 44, and 51%, respectively, in each time period (1995–1998: HR = 0.75, P = 0.004; 1999–2002: HR = 0.56, P < 0.001; 2003–2006: HR = 0.49, P < 0.001) as compared to the first time period (1991–1994). The effect o...
Source: Breast Cancer Research and Treatment - November 13, 2009 Category: Cancer & Oncology Tags: Breast Cancer Research and Treatment Source Type: journals

Cyclin D1 is a direct target of JAG1-mediated Notch signaling in breast cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract The Notch ligand, JAG1 is associated with breast cancer recurrence. Herein, we report on a genomics approach to elucidate mechanisms downstream of JAG1 that promote breast cancer growth. In a survey of 46 breast cancer cell lines, we found that triple negative (TN; basal and mesenchymal ER-, PR-, and Her2-negative) lines express JAG1 at significantly higher levels than do HER2+ or luminal (ER+) Her2− cell lines. In contrast to the luminal lines tested (T47D and MCF7), TN breast cancer cell lines (HCC1143 and MDA MB231) display high-level JAG1 expression and growth inhibition with RNA interference-...
Source: Breast Cancer Research and Treatment - November 13, 2009 Category: Cancer & Oncology Tags: Breast Cancer Research and Treatment Source Type: journals

Absence of transforming growth factor-{beta} type II receptor is associated with poorer prognosis in HER2-negative breast tumours.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CONCLUSIONS: To the best of our knowledge, this is the first report indicating the relevance of HER2 status in discriminating TGF-betaRII as a prognostic marker for DFS and OS in human BC. These data indicate that TGF-betaRII protein analysis in tumour cells could be introduced in clinical practice as additional prognostic biomarker in HER2-negative BC. PMID: 19914962 [PubMed - as supplied by publisher] (Source: Ann Oncol)
Source: Ann Oncol - November 13, 2009 Category: Cancer & Oncology Authors: Paiva CE, Drigo SA, Rosa FE, Moraes Neto FA, Caldeira JR, Soares FA, Domingues MA, Rogatto SR Tags: Ann Oncol Source Type: journals

Prognostic impact of ALDH1 in breast cancer: a story of stem cells and tumor microenvironmentEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In this study, we sought to examine the prognostic relevance of ALDH1, a putative cancer stem cell marker, by immunohistochemistry. The four cohorts analyzed included an adjuvantly treated series of 245 invasive cancers, a neoadjuvantly treated series of 34 cases, and two series of 58 and 40 triple negative cases, respectively. Both tumor cell and stromal expression for ALDH1 was evaluated, where possible. Tumor cell ALDH1 expression significantly correlated only with basal-like and HER2 tumor types in the adjuvant series and tumor grade in the neoadjuvant cohort. No significant enrichment for ALDH1 positive cells was...
Source: Breast Cancer Research and Treatment - November 12, 2009 Category: Cancer & Oncology Tags: Breast Cancer Research and Treatment Source Type: journals

Inhibition of Lipocalin 2 Impairs Breast Tumorigenesis and MetastasisEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Lipocalin 2 (LCN2; also known as NGAL) is a secreted glycoprotein and its elevated expression has been observed in breast cancers. However, the importance of LCN2 in breast tumorigenesis is unclear. Here, we employed a spontaneous mammary tumor mouse model showing that MMTV-ErbB2(V664E) mice lacking mouse LCN2 had significantly delayed mammary tumor formation and metastasis with reduced matrix metalloproteinase-9 activity in the blood. LCN2 expression is upregulated by HER2/phosphoinositide 3-kinase/AKT/NF-B pathway. Decreasing LCN2 expression significantly reduced the invasion and migration ability of HER2+ breast cancer ...
Source: Cancer Research - November 12, 2009 Category: Cancer & Oncology Authors: Leng, X., Ding, T., Lin, H., Wang, Y., Hu, L., Hu, J., Feig, B., Zhang, W., Pusztai, L., Symmans, W. F., Wu, Y., Arlinghaus, R. B. Tags: Cell, Tumor, and Stem Cell Biology Source Type: journals

Heat Shock Protein 90 Inhibitors: New Mode of Therapy to Overcome Endocrine ResistanceEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
We examined whether the heat shock protein 90 (HSP90) inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG) can inhibit the growth of aromatase inhibitor–resistant breast cancers and the mechanisms by which 17-DMAG affects proliferation. Aromatase inhibitor–responsive MCF-7aro and aromatase inhibitor–resistant LTEDaro breast epithelial cells were used in this study. We observed that 17-DMAG inhibited proliferation in both MCF-7aro and LTEDaro cells in a dose-dependent manner. 17-DMAG induced apoptosis and G2 cell cycle arrest in both cell lines. Although inhibition of HSP90 decreased t...
Source: Cancer Research - November 12, 2009 Category: Cancer & Oncology Authors: Wong, C., Chen, S. Tags: Experimental Therapeutics, Molecular Targets, and Chemical Biology Source Type: journals

Preclinical study of prolonged administration of trastuzumab as combination therapy after disease progression during trastuzumab monotherapyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion We established in vivo trastuzumab PD models, in which trastuzumab monotherapy ceases to have antitumor activity during the treatment. The mechanisms of PD with trastuzumab are considered to involve both reversible changes in the gene expression profiles in tumor tissues and a decrease of ADCC activity in the host. Our present results demonstrated that trastuzumab showed antitumor activity in combination with taxanes or capecitabine even though it showed no antitumor activity as a monotherapy, suggesting a clinical relevance of treatment with trastuzumab as a combination therapy beyond PD. ...
Source: Cancer Chemotherapy and Pharmacology - November 10, 2009 Category: Cancer & Oncology Tags: Cancer Chemotherapy and Pharmacology Source Type: journals

ASCO report on major research advances in cancer treatment, prevention, and screening 2009Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Source: J Clin Oncol Area: News Each year, the American Society of Clinical Oncology (ASCO) independently reviews advances in clinical cancer research and identifies those that have had the greatest impact on patient care. The report for 2009 highlights 51 of the most significant studies, including 15 that the editors consider are major advances that have the potential to lead to a reduction in mortality from cancer. The following therapeutic advances were addressed: . First targeted treatment for gastric cancer: large clinical trial found that adding trastuzumab to standard chemotherapy for adv...
Source: NeLM - Oncology - November 10, 2009 Category: Cancer & Oncology Source Type: organizations

A Novel Toll-Like Receptor 9 Agonist Cooperates with Trastuzumab in Trastuzumab-Resistant Breast Tumors through Multiple Mechanisms of Action.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CONCLUSIONS: We showed a cooperative effect of IMO plus trastuzumab in trastuzumab-resistant breast cancers due to IMO direct antitumor and antiangiogenic activity and antibody-dependent cell-mediated cytotoxicity enhancement. Moreover, we provided first evidence of a toll-like receptor 9/HER interaction at membrane level as novel mechanism of action. Altogether, we propose IMO plus trastuzumab as an effective strategy in trastuzumab-resistant breast cancers. (Clin Cancer Res 2009;15(22):6921-30). PMID: 19903791 [PubMed - as supplied by publisher] (Source: Cell Research)
Source: Cell Research - November 10, 2009 Category: Cytology Authors: Damiano V, Garofalo S, Rosa R, Bianco R, Caputo R, Gelardi T, Merola G, Racioppi L, Garbi C, Kandimalla ER, Agrawal S, Tortora G Tags: Clin Cancer Res Source Type: journals

HER2 Status Predicts Recurrence of Small Breast CancersEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In women treated for small (1 cm or less), node-negative breast cancers, HER2 positivity is strongly linked to recurrence and poorer disease-free survival, according to the results of two studies reported in the November 2nd online issue of the Journal of Clinical Oncology. Reuters Health Information (Source: Medscape Ob/Gyn & Women's Health Headlines)
Source: Medscape Ob/Gyn & Women's Health Headlines - November 9, 2009 Category: OBGYN Tags: Hematology-Oncology Source Type: info

In this issueEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The appropriate level of iron in a cell is critical to its health: too much and you have hereditary hemochromatosis; too little and it's iron deficiency anemia. Hepcidin-25, expressed in the liver, appears to be the principal homeostatic regulator of iron although two other forms of hepcidin are known, hepcidin-20 and hepcidin-22. Their function(s) have not been explicated, possibly they are antibacterial. Complicating matters further, up- and down-regulation of the various hepcidins are not regulated synchronously in various cell lines and primary hepatocyte cultures. To get a grip on this confusion, Hosoki et al. develop...
Source: Proteomics. Clinical Applications - November 9, 2009 Category: Biochemistry Tags: In this issue Source Type: journals

Intrinsic subtype-associated changes in the plasma proteome in breast cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In this study, we compared the plasma proteome of patients with Luminal A, Luminal B, HER2+, and Basal subtype with plasma from healthy individuals. Protein changes were considered significant if q-value (false discovery rate) was less than 5%. The highest number of changes in the plasma proteome was observed in patients with Luminal type B followed by Basal type breast cancers. The plasma proteome of Luminal A and HER2+ breast cancer patients did not differ significantly from healthy individuals. In Basal breast cancer, a significant number of plasma proteins were downregulated compared with healthy individuals. Acute pha...
Source: Proteomics. Clinical Applications - November 9, 2009 Category: Biochemistry Authors: Harikrishna Nakshatri, Guihong Qi, Jinsam You, Bemis Kerry, Bryan Schneider, Robin Zon, Charles Buck, Fred Regnier, Mu Wang Tags: Research Articles Source Type: journals

Triple-negative breast cancer: correlation between imaging and pathological findingsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion Our results suggest that the imaging findings might be useful in diagnosing triple-negative breast cancer. Content Type Journal ArticleCategory BreastDOI 10.1007/s00330-009-1656-3Authors Eun Sook Ko, Korea Cancer Centre Hospital Department of Radiology 215-4 Gongneung-Dong, Nowon-Gu Seoul 139-706 KoreaByung Hee Lee, Korea Cancer Centre Hospital Department of Radiology 215-4 Gongneung-Dong, Nowon-Gu Seoul 139-706 KoreaHyun-A Kim, Korea Cancer Centre Hospital Department of Surgery Seoul KoreaWoo-Chul Noh, Korea Cancer Centre Hospital Department of Surgery Seoul KoreaMin Suk Kim, Korea Cancer Ce...
Source: European Radiology - November 6, 2009 Category: Radiology Tags: European Radiology Source Type: journals

Targeting Human Epidermal Growth Factor Receptor Signaling with the Neuregulin's Heparin-binding Domain [Glycobiology and Extracellular Matrices]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
A major limitation in biopharmaceutical development is selectively targeting drugs to diseased tissues. Growth factors and viruses have solved this problem by targeting tissue-specific cell-surface heparan sulfates. Neuregulin (NRG), a growth factor important in both nervous system development and cancer, has a unique heparin-binding domain (HBD) that targets to cell surfaces expressing its HER2/3/4 receptors (Esper, R. M., Pankonin, M. S., and Loeb, J. A. (2006) Brain Res. Rev. 51, 161–175). We have harnessed this natural targeting ability of NRG by fusing the HBD of NRG to soluble HER4. This fusion protein retains ...
Source: Journal of Biological Chemistry - November 6, 2009 Category: Chemistry Authors: Ma, Z., li, Q., An, H., Pankonin, M. S., Wang, J., Loeb, J. A. Tags: Glycobiology and Extracellular Matrices Source Type: journals

Small HER2-Positive Breast Tumors Warrant Adjuvant TreatmentEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
HER2-positive breast cancers, even when they are small, are twice as likely to recur as are small HER2-negative breast cancers, according to results from 2 new studies. Furthermore, when small HER2-positive... (Source: OncologySTAT What Patients Are Reading)
Source: OncologySTAT What Patients Are Reading - November 6, 2009 Category: Cancer & Oncology Source Type: info

Fatty acid synthase activity regulates HER2 extracellular domain shedding into the circulation of HER2-positive metastatic breast cancer patients.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Clinicopathological assessment of the functional relationship between the HER2 oncogene and tumor-associated fatty acid synthase (FASN) is largely precluded because immunohistochemical and/or mRNA studies should be performed in biopsies from breast cancer patients. We here sought to determine whether serum FASN (sFASN) could associate with circulating HER2 extracellular domain (HER2 ECD) in the blood of metastatic breast cancer (MBC) patients. Concentrations of serum FASN and HER2 ECD were measured with ELISA in sera retrospectively obtained from 201 patients with metastatic breast cancer (MBC) and 31 healthy subjects....
Source: International Journal of Oncology - November 5, 2009 Category: Cancer & Oncology Authors: Vazquez-Martin A, Fernandez-Real JM, Oliveras-Ferraros C, Navarrete JM, Martin-Castillo B, Del Barco S, Brunet J, Menendez JA Tags: Int J Oncol Source Type: journals

M. D. Anderson News Release: Early Stage, HER2 Positive Breast Cancer Patients at Increased Risk of RecurrenceEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Large study finds subset of women that may need additional therapy HOUSTON , Nov. 2, 2009- Early-stage breast cancer patients with HER2 positive tumors one centimeter or smaller are at significant risk of recurrence of their disease, compared... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 5, 2009 Category: Pharmaceuticals Source Type: clinical trials

Early-stage, HER2-positive Breast Cancer Patients At Increased Risk Of RecurrenceEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Early-stage breast cancer patients with HER2 positive tumors one centimeter or smaller are at significant risk of recurrence of their disease, compared to those with early-stage disease who do not express the aggressive protein, according to a new study. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - November 5, 2009 Category: Science Source Type: news

FEC with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: Final results of Fin-Her TrialEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
This report published early online in the Journal of Clinical Oncology presents the final results of the trial. The study involved 1010 women with axillary node-positive or high-risk node-negative breast cancer, randomised to receive 3 cycles of docetaxel or vinorelbine, followed in both groups by 3 cycles of fluorouracil, epirubicin, and cyclophosphamide (FEC). Women with HER2-positive cancer (n = 232) were further assigned to either receive or not receive trastuzumab for 9 weeks with docetaxel or vinorelbine (the authors note that in all other trials reported to date of adjuvant trastuzumab for early HER2-posi...
Source: NeLM - Oncology - November 5, 2009 Category: Cancer & Oncology Source Type: organizations

Breast cancer 'changes' as it spreadsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion This study reports that the characteristics of breast tumours may change as they spread through the body. It gives further insight into the behaviour of cancer cells, but its findings will require confirmation in other studies. Other points of note are: Although the study included samples from a relatively large number of women, comparatively few had certain characteristics (for example, those who tested negative for all three proteins). As such, the findings will need to be confirmed by other studies. The study only looked at lymph node metastases (spread). It cannot show what happens when the cancerous...
Source: NHS News Feed - November 4, 2009 Category: Consumer Health News Tags: Cancer Source Type: news

HER2 Boosts Recurrence Risk Even for Small Breast Cancers (CME/CE, with audio)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Small, early-stage breast cancers that are HER2-positive carry a substantial risk of recurrence and metastasis that may suggest a need for trastuzumab (Herceptin) therapy, researchers said. (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - November 4, 2009 Category: Hematology Source Type: news

It's Safe To Treat HER2-Positive Breast Cancer With Trastuzumab And Adjuvant Radiation, Study FindsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Standard adjuvant treatment for HER2-positive breast cancer patients, following primary surgery for their cancer, is Trastuzumab (Herceptin) - typically used in combination with chemotherapy. However, a new study by researchers at Fox Chase Cancer Center reports that it may be safe to treat these patients with both Trastuzumab and adjuvant radiation therapy. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - November 4, 2009 Category: Consumer Health News Tags: Breast Cancer Source Type: news

Drug Could Help Treat Small HER2-Positive Breast TumorsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Title: Drug Could Help Treat Small HER2-Positive Breast TumorsCategory: Health NewsCreated: 11/3/2009 12:10:00 PMLast Editorial Review: 11/4/2009 (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - November 4, 2009 Category: Cancer & Oncology Source Type: consumer

Asian Oncology Summit issues consensus statements on the management of various cancersEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Source: Lancet Oncology Area: News The Asian Oncology summit has issued consensus statements on the management of the following conditions in the context of basic, limited, enhanced, and maximum health-care resource availability: . Management of HER2-positive breast cancer in Asia . Management of the neck after chemoradiotherapy for head and neck cancers in Asia . Management of T-cell and natural-killer-cell neoplasms in Asia . First-line systemic treatment of advanced stage non-small-cell lung cancer in Asia . Management of hepatocellular carcinoma in Asia . Management of endometrial cance...
Source: NeLM - Oncology - November 4, 2009 Category: Cancer & Oncology Source Type: organizations

Drug Could Help Treat Small HER2-Positive Breast TumorsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Researcher urges studies to determine benefits of anti-HER2 therapies Source: HealthDay Related MedlinePlus Topic: Breast Cancer (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - November 3, 2009 Category: Consumer Health News Source Type: consumer

Early-stage, HER2-positive breast cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Early-stage patients with breast cancer with HER2 positive tumors one centimeter or smaller are at significant risk of recurrence of their disease, in comparison to those with early-stage disease who do not express the aggressive protein, as per a research studyled by scientists at The University of Texas M. D. Anderson Cancer Center........ (Source: Medicineworld.org: New Article Alert)
Source: Medicineworld.org: New Article Alert - November 3, 2009 Category: Consumer Health News Source Type: info

Study finds it's safe to treat HER2-positive breast cancer with trastuzumab and adjuvant radiationEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Fox Chase Cancer Center) Standard adjuvant treatment for HER2-positive breast cancer patients, following primary surgery for their cancer, is trastuzumab (herceptin) -- typically used in combination with chemotherapy. However, a new study by researchers at Fox Chase Cancer Center reports that it may be safe to treat these patients with both trastuzumab and adjuvant radiation therapy. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 3, 2009 Category: Global & Universal Source Type: news

Microarray-Based Determination of Estrogen Receptor, Progesterone Receptor, and HER2 Receptor Status in Breast Cancer.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CONCLUSION: Microarray-based readout of ER, PR, and HER2 shows a high concordance with immunohistochemistry/CISH and provides an additional, objective, and quantitative assessment of tumor receptor status in breast cancer. (Clin Cancer Res 2009;15(22):7003-11). PMID: 19887485 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - November 3, 2009 Category: Cancer & Oncology Authors: Roepman P, Horlings HM, Krijgsman O, Kok M, Bueno-de-Mesquita JM, Bender R, Linn SC, Glas AM, van de Vijver MJ Tags: Clin Cancer Res Source Type: journals